EA202000218A1 - PHARMACEUTICAL COMPOSITION (OPTIONS), APPLICATION OF PHARMACEUTICAL COMPOSITION (OPTIONS) - Google Patents

PHARMACEUTICAL COMPOSITION (OPTIONS), APPLICATION OF PHARMACEUTICAL COMPOSITION (OPTIONS)

Info

Publication number
EA202000218A1
EA202000218A1 EA202000218A EA202000218A EA202000218A1 EA 202000218 A1 EA202000218 A1 EA 202000218A1 EA 202000218 A EA202000218 A EA 202000218A EA 202000218 A EA202000218 A EA 202000218A EA 202000218 A1 EA202000218 A1 EA 202000218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
options
pharmaceutical
bronchitis
pneumonia
Prior art date
Application number
EA202000218A
Other languages
Russian (ru)
Inventor
Александр Григорьевич ЧУЧАЛИН
Тамерлан Асланбекович БАЛАЕВ
София Яковлевна Скачилова
Ирина Борисовна БАДЮГИНА
Татьяна Николаевна МОЛОСТОВА
Юрий Тихонович КАЛИНИН
Оксана Владимировна ПРОСКУРИНА
Анастасия Николаевна ДУКЛЕР
Original Assignee
Александр Григорьевич ЧУЧАЛИН
Тамерлан Асланбекович БАЛАЕВ
София Яковлевна Скачилова
Ирина Борисовна БАДЮГИНА
Татьяна Николаевна МОЛОСТОВА
Юрий Тихонович КАЛИНИН
Оксана Владимировна ПРОСКУРИНА
Анастасия Николаевна ДУКЛЕР
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Александр Григорьевич ЧУЧАЛИН, Тамерлан Асланбекович БАЛАЕВ, София Яковлевна Скачилова, Ирина Борисовна БАДЮГИНА, Татьяна Николаевна МОЛОСТОВА, Юрий Тихонович КАЛИНИН, Оксана Владимировна ПРОСКУРИНА, Анастасия Николаевна ДУКЛЕР filed Critical Александр Григорьевич ЧУЧАЛИН
Publication of EA202000218A1 publication Critical patent/EA202000218A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к медицине, к фармацевтической промышленности, а именно к фармацевтическим композициям, предназначенным для лечения таких бронхолегочных заболеваний, как бронхиальная астма, хроническая обструктивная болезнь легких, бронхиты, пневмонии. Достигнут технический результат созданием вариантов фармацевтической композиции на основе блокатора М-холинергических рецепторов йодметилат тропинового эфира d,l-(2-гидроксиметил-2-фенил)масляной кислоты и селективного 2-агониста сальбутамола гемисукцината, а также вариантов применения фармацевтической композиции для лечения таких бронхолегочных заболеваний, как бронхиальная астма, хроническая обструктивная болезнь легких, бронхиты, пневмонии, обеспечивающей повышение эффективности действия препарата благодаря синергизму, снижение терапевтической дозы по сравнению с монопрепаратами, минимизацию побочных реакций. Изобретение опробовано практически, фармацевтические композиции, в каждом из предложенных вариантов, промышленно применимы и найдут широкое применение в фармацевтической промышленности и медицине.The invention relates to medicine, to the pharmaceutical industry, namely to pharmaceutical compositions intended for the treatment of such bronchopulmonary diseases as bronchial asthma, chronic obstructive pulmonary disease, bronchitis, pneumonia. A technical result has been achieved by creating variants of a pharmaceutical composition based on a blocker of M-cholinergic receptors iodomethylate tropine ester d, l- (2-hydroxymethyl-2-phenyl) butyric acid and a selective 2-agonist salbutamol hemisuccinate, as well as options for using the pharmaceutical composition for the treatment of such bronchopulmonary diseases such as bronchial asthma, chronic obstructive pulmonary disease, bronchitis, pneumonia, which provides an increase in the effectiveness of the drug due to synergism, a decrease in the therapeutic dose compared to monopreparations, and minimization of side reactions. The invention has been tested in practice, pharmaceutical compositions, in each of the proposed variants, are industrially applicable and will find wide application in the pharmaceutical industry and medicine.

EA202000218A 2018-01-23 2018-01-23 PHARMACEUTICAL COMPOSITION (OPTIONS), APPLICATION OF PHARMACEUTICAL COMPOSITION (OPTIONS) EA202000218A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2018/000023 WO2019147154A1 (en) 2018-01-23 2018-01-23 Pharmaceutical formulation (embodiments) and use of a pharmaceutical formulation (embodiments)

Publications (1)

Publication Number Publication Date
EA202000218A1 true EA202000218A1 (en) 2021-03-03

Family

ID=67395035

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202000218A EA202000218A1 (en) 2018-01-23 2018-01-23 PHARMACEUTICAL COMPOSITION (OPTIONS), APPLICATION OF PHARMACEUTICAL COMPOSITION (OPTIONS)

Country Status (2)

Country Link
EA (1) EA202000218A1 (en)
WO (1) WO2019147154A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113476428B (en) * 2021-01-28 2022-03-29 朗天药业(湖北)有限公司 Salbutamol sulfate solution for inhalation and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2054932C1 (en) * 1992-06-26 1996-02-27 Всероссийский научный центр по безопасности биологически активных веществ Inhalation composition for bronchial asthma treatment
EP1729724A4 (en) * 2003-12-31 2008-07-23 Cydex Inc Inhalent formulation containing sulfoalkyl ether gamma-cyclodextryn and corticosteroid
WO2007034207A2 (en) * 2005-09-25 2007-03-29 Cipla Limited Troventol formulation
CN102695496B (en) * 2009-12-23 2014-10-01 奇斯药制品公司 Aerosol formulation for COPD

Also Published As

Publication number Publication date
WO2019147154A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CR20210552A (en) Nlrp3 inflammasome inhibitors
CY1123391T1 (en) (2S)-N-[(1S)-1-CYANO-2-PHYNYLATHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS INHIBITORS OF DIPEPTYLYPEPTIDASE I
CR20210045A (en) Nlrp3 inflammasome inhibitors
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
PH12015500375A1 (en) Nep inhibitors for treating diseases characterized by atrial enlargemenet or remodeling
BR112013021566A2 (en) compound of formula, or a pharmaceutically acceptable salt or adduct thereof and method of preventing and / or treating an individual comprising administering to said individual a therapeutically effective amount of a compound of formula
EA201790653A1 (en) METHOD OF TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS
JP2016516074A5 (en)
BR112021021738A2 (en) Amino quinazoline derivatives as p2x3 inhibitors
EA201791780A1 (en) TIOTROPY INHALATION SOLUTION FOR NONBULIZER SPRAYING
EA200870469A1 (en) NEW, CONTAINING NIMESULIDE, PHARMACEUTICAL COMPOSITIONS WITH LOW DOSE, THEIR RECEPTION AND APPLICATION
EA201891931A1 (en) NEW INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE GAMMA
BR112021021195A2 (en) Methods for treating or preventing asthma by administering an il-33 antagonist
RU2016132762A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A 15-HEPC AND METHODS FOR TREATING ASTHMA AND LUNG DISEASES WITH THEIR APPLICATION
WO2016168553A8 (en) Deuterated obeticholic acid
BR112022009209A2 (en) AMIGO DERIVATIVE AND METHOD OF PREPARATION AND USE IN MEDICINE
MX2021010568A (en) Leucine, acetyl leucine, and related analogs for treating disease.
CO2022008616A2 (en) Oral pharmaceutical composition comprising carbamate compound and method of preparation therefor
EA202000218A1 (en) PHARMACEUTICAL COMPOSITION (OPTIONS), APPLICATION OF PHARMACEUTICAL COMPOSITION (OPTIONS)
RU2017126153A (en) Pharmaceutical combination
BR112014007684A2 (en) rhinitis treatment
BR112022018979A2 (en) DRUG FOR PAIN TREATMENT
BR112021020279A2 (en) Pyridopyrimidine derivatives as p2x3 inhibitors
MX2022004809A (en) Compositions for preventing or treating chronic obstructive pulmonary diseases (copd).
RU2013126798A (en) COMBINED THERAPY BY DEXAMETASONE